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SUMMARY
Access to high quality antibodies is a necessity for the study of histones and their posttranslational 
modifications (PTMs). Here we debut The Histone Antibody Specificity Database (http://
www.histoneantibodies.com), an online and expanding resource cataloguing the behavior of 
widely used commercially available histone antibodies by peptide microarray. This interactive 
web portal provides a critical resource to the biological research community who routinely use 
these antibodies as detection reagents for a wide range of applications.
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Histones and their numerous posttranslational modifications (PTMs) are fundamental to the 
process of cell fate decision-making and organismal development. Consistent with this, 
studies have shown that both histone mutation and PTM misregulation contribute to the 
initiation and progression of a wide number of human diseases, including cancer and 
neurological disorders (Bannister and Kouzarides, 2011; Dawson and Kouzarides, 2012; 
Funato et al., 2014; Jakovcevski and Akbarian, 2012; Lewis et al., 2013; Rothbart and 
Strahl, 2014). Histone modifications function in part as docking sites for effector proteins 
harboring specialized, evolutionarily conserved domains that ‘read’ the single or 
combinatorial modification states of histones (Gardner et al., 2011; Jenuwein and Allis, 
2001; Strahl and Allis, 2000).
The mass production and distribution of PTM-specific histone antibodies (more than 1,000 
are commercially available to date) has greatly facilitated the study of these histone marks 
and their impact on chromatin function (Perez-Burgos et al., 2004; Turner and Fellows, 
1989). Histone PTM antibodies are essential for numerous applications in chromatin 
research, including immunoblotting, immunostaining, and chromatin immunoprecipitation 
(ChIP). Indeed, large-scale epigenomics ‘roadmap’ efforts like the Encyclopedia of DNA 
Elements (ENCODE) projects depend on these antibodies for genome-wide mapping of 
histone PTM distribution (Ernst et al., 2011; Gerstein et al., 2010; Kharchenko et al., 2011). 
However, recent studies have made some surprising and alarming observations regarding the 
behavior of histone PTM antibodies, including off-target recognition, strong influence by 
neighboring PTMs, and an inability to distinguish the modification state on a particular 
residue (e.g., mono-, di-, or tri-methyl lysine) (Bock et al., 2011; Egelhofer et al., 2011; 
Fuchs et al., 2011; Fuchs and Strahl, 2011; Hattori et al., 2013; Nishikori et al., 2012; 
Rothbart et al., 2012e). Consequently, poor antibody choice can lead to misinformed 
conclusions regarding the location and function of the histone PTM being queried (Baker, 
2015). As our understanding of how histone PTMs contribute to normal biology and human 
disease depends on the quality of the antibodies being used, continued rigorous quality 
control is needed for accurate data interpretation and continued progress in the field.
Herein, we describe an interactive web resource, The Histone Antibody Specificity 
Database, for histone PTM antibody characterization built on our recently developed high-
density histone peptide microarray platform (Fuchs et al., 2011; Rothbart et al., 2012b). This 
open-access database, which at the time of publication provides characterization data on 
over 100 of the most frequently used and cited commercially available histone PTM 
antibodies, serves as an interactive, sustained and evolving platform for the interrogation of 
antibody specificity that will greatly aid epigenetics researchers in making more informed 
histone antibody choices. We provide several vignettes of common antibody behavior drawn 
from this resource, including off-target recognition and sensitivity to neighboring PTMs, and 
we highlight how these behaviors could influence the conclusions made from their use in 
various applications.
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The Histone Antibody Specificity Database
We recently developed a high-density histone peptide microarray platform consisting of a 
library of over 250 purified biotinylated histone peptides harboring PTMs (lysine 
acetylation, lysine/arginine methylation, and serine/threonine phosphorylation) alone and in 
relevant combinations that are largely derived from mass spectrometry-based proteomics 
datasets (Table S1) (Pesavento et al., 2008; Sidoli et al., 2012; Young et al., 2009; Young et 
al., 2010). This platform allows for robust and comprehensive characterization of the 
behavior of histone-interacting proteins, including the specificity of histone antibodies 
(Figure 1A) (Cai et al., 2013; Fuchs et al., 2011; Rothbart et al., 2013; Rothbart et al., 2012a; 
Rothbart et al., 2012e). Notably, antibody reactivity with differing modification states (e.g., 
mono-, di- and trimethyl lysine) and the influence of epitope recognition by neighboring 
histone PTMs can be determined with high precision. With this platform, we analyzed over 
100 histone PTM antibodies that are commercially available from nine suppliers who market 
these products to specifically recognize various methylated, acetylated, and phosphorylated 
residues (and their combinations) on the core and variant histones, yielding over 25,000 
specific binding measurements (Figure 1B and Table S2).
To create a versatile platform that is easily accessible to the broad scientific community for 
interrogation of histone antibody specificity data, we built an interactive web platform, 
www.histoneantibodies.com (Figure 1C), which utilizes the D3js JavaScript library. Users 
can query the database by search bar (Figure 1C; top) or by histone and sequence context 
(Figure 1C; bottom) for antibody data specified by PTM of interest, histone, residue, 
company, or product number (Table S2). All datasets for a particular PTM of interest are 
presented together to allow users to make direct comparisons. Data are presented on the 
website as interactive heat maps (Figures S1A and S1B) and bar graphs (Figure S1B). 
Hovering over individual data points in these graphs gives the user information on 
corresponding peptide length, PTMs, and sequence context (Table S1). For heat maps, array 
signal intensities are ordered from strongest (yellow) to weakest (blue) relative to a 
reference target (black) – the peptide harboring the PTM(s) on the antibody product label. 
All peptides containing the reference target are outlined in red.
For bar graphs, array results are presented as normalized mean intensities ± S.E.M. on a 
scale from 0 (undetectable binding) to 1 (strong binding). The target peptide is depicted as a 
green bar. Orange bars indicate target-containing peptides that display enhanced signal 
compared to the reference. These are PTM combinations that enhance antibody binding. 
Light blue bars indicate target-containing peptides that display a diminished signal 
compared to the reference. These are PTM combinations that inhibit antibody binding. Gray 
bars indicate off-target peptides. Analysis of all tested histone PTM antibodies allowed us to 
bin unfavorable behavior into three general categories: 1) an inability to distinguish states of 
methylated lysine, 2) sensitivity to neighboring PTMs, and 3) recognition of off-target 
modifications. Examples of these types of behavior are discussed below.
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Distinguishing States of Methylated Lysine
Of the 38 di- and tri-methyllsyine antibodies screened, 16 cross-react with lower states of 
lysine methylation on a target residue, and one recognized a higher state of lysine 
methylation. Notably, this does not appear to be a general property of methyllysine 
antibodies to a particular target residue. For example, analysis of five H3K4me3 antibodies 
shows that several cross-react with H3K4me2 peptides, while others are selective for the 
H3K4me3 mark (Figure 2A, left). This is also true for H3K4me2 antibodies, some of which 
cross-react with H3K4me1 peptides (Figure 2A, right). Importantly, the three states of 
methylation at H3K4 have reportedly differential regulatory functions (Barski et al., 2007), 
yet analysis of the genomic distribution of these marks by ChIP-Seq in HEPG2 cells, using 
antibodies that cross react with lower order methylation states by microarray, shows 
overlapping signal for H3K4me3 and H3K4me2 across transcription start sites and gene 
bodies (Figure S2A), and for H3K4me2 and H3K4me1 across enhancer elements (Figure 
S2B). Collectively, these results highlight the importance of antibody choice for accurately 
discerning between various states of lysine methylation and suggest antibody cross-
reactivity may contribute to inaccurate mapping of histone lysine methylation states in 
genome-wide analyses due to antibody cross-reactivity.
Sensitivity to neighboring PTMs
Neighboring PTMs can impact not only the ability of a reader domain to bind its target 
modification but also the ability of histone PTM antibodies to recognize their target epitopes 
(Bock et al., 2011; Fuchs et al., 2011). As an example, H3K9me3 antibodies show varying 
degrees of sensitivity – both enhanced and perturbed epitope recognition – to neighboring 
PTMs that surround H3K9 (Figure S2C). Most notably, H3K9me3 antibodies we screened 
show differential tolerance to neighboring H3S10 phosphorylation (Figure 2B; left) – a 
mitotic combinatorial ‘methyl/phospho switch’ known to eject proteins like heterochromatin 
protein 1 (HP1), for example, from mitotic chromatin (Fischle et al., 2005; Hirota et al., 
2005). Neighboring H3K9me3 also impacts epitope recognition by H3S10p antibodies 
(Figure 2B; middle). The H3K9me3 and H3S10p antibodies insensitive to this ‘methyl/
phospho switch’ cannot distinguish between dually marked H3 tails and isolated H3K9me3 
or H3S10p marks. However, several antibodies developed to recognize this methyl/phospho 
PTM combination are capable of this distinction by microarray analysis (Figure 2B; right). 
Collectively, these findings suggests that H3K9me3 and H3S10p antibodies sensitive to 
neighboring phosphorylated and methylated residues, respectively, under-represent these 
singly-marked histone H3 populations in mitosis, and that combinations of all three selective 
reagents may be required to accurately detect and map this dually marked chromatin 
signature.
Consistent with our previous observations (Rothbart et al., 2012e), microarray analysis 
shows that site-specific H4 acetyl antibodies preferentially bind epitopes with iterative 
increases in acetylation content (Figure 2C). For example, all of the H4K5ac antibodies 
screened show enhanced signal on peptides containing H4K5ac and one or more H4Kac 
sites, with iterative increases in acetylation content (up to 4 sites on a single peptide) being 
preferred epitopes for the majority of H4 acetyl antibodies screened. Importantly, this does 
not appear to be due to charge masking, as an H4K12ac peptide with all other lysines 
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mutated to glutamine (K5, K8, K16, and K20) is only recognized by H4K12ac antibodies 
and by a tetra-acetyl H4 antibody (4ac) that also recognizes H4K12ac peptides in isolation 
(Figure 2C).
Off-target PTM recognition
A significant number of histone PTM antibodies that were screened demonstrated cross-
reactivity with unintended modifications. For example, while H3K9me3 Ab2 is insensitive 
to neighboring H3S10p (Figure 2B; left) and does not recognize lower-order methylation 
states of H3K9 (Figure 2D), this antibody suffers from off-target recognition of other tri-
methylated lysine residues, including H3K27me3, H3K23me3, and H3K18me3 (Figures 2D 
and S3). While the latter two PTMs are found in lower abundance in cells (Lin et al., 2014) 
and may therefore not be problematic under physiologic conditions, cross-reactivity with 
H3K27me3 may be problematic for this antibody, enriching for signals present in regions of 
facultative heterochromatin where H3K9me3 may or may not reside.
H3K9 and H3K27 are both found in an ARKS motif, and indeed, we and others have shown 
that the H3K9 methyltransferase G9a can modify H3K27 in vitro ((Tachibana et al., 2001) 
and not shown). While this may serve as an explanation for antibody mis-targeting between 
these sites, we note that this issue of off-target methyllysine reactivity does not appear to be 
restricted to residues found in similar sequence contexts. Indeed, analysis of H3K27me3 
antibodies shows that several preferentially bind H3K4me3 peptides (Figure 3A). This off-
target recognition is strongly enhanced when H3K4me3 is presented in combination with 
neighboring acetylation marks, a native context of H3K4me3 found in cells (Taverna et al., 
2007). To test whether this cross-reactivity could be seen in cells, we performed 
immunoblots with this antibody on whole-cell extracts from the budding yeast 
Saccharomyces cerevisiae, an organism whose chromatin lacks H3K27 methylation (Garcia 
et al., 2007). To our surprise, a 17kDa band corresponding to signal from histone H3 was 
detected with H3K27me3 Ab3 (Figure 3B; left). Furthermore, this 17kDa band was 
undetectable following deletion of SET1, the sole H3K4 methyltransferase in budding yeast 
(Briggs et al., 2002) (Figure 3B; right), demonstrating cellular cross-reactivity of this 
H3K27me3 antibody with H3K4me3-marked histones in cells and presenting a potential 
conundrum for bivalency readouts (Bernstein et al., 2006) featuring these antibodies.
Another type of antibody cross-reactivity we observed was epitope recognition in the 
absence of a target PTM. This can be seen with several analyzed H3S10p antibodies that 
recognize H3(1-20) peptides combinatorially modified in various ways in the presence 
(Figure 3C; top) or absence (Figure 3C; bottom) of this phosphorylation mark. H3S10p is a 
dynamic histone PTM found in low abundance at transcriptionally active genes in interphase 
cells (Davie, 2003) and is highly enriched in mitotic chromatin during condensation (Wei et 
al., 1999). To confirm the behavior observed with H3S10p antibodies, we tracked the cell 
cycle dynamics of this PTM using an H3S10p antibody the arrays would classify as specific 
for this mark (Ab1) and one the arrays would classify as a pan N-terminal H3 antibody 
(Ab2). HeLa cell were arrested at G1/S by double thymidine block and extracts were 
immunoblotted at time points following release to track H3S10p through mitosis (Figure 
3D). Consistent with previous observations (Davie, 2003; Wei et al., 1999), H3S10p Ab1 
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signal was weak through S phase and was pronounced in mitotic extracts (Figure 3D). In 
contrast, H3S10p Ab2 signal was equal in all cell cycle fractions, consistent with 
characterization by array of this antibody’s behavior as an N-terminal specific, pan H3 
antibody.
ChIP validation of antibody behavior
A gold standard for histone PTM antibodies is their utility in chromatin 
immunoprecipitation (ChIP) assays. We therefore questioned whether characterization of 
antibodies by peptide microarray could inform on target recognition in ChIP. We chose two 
H3K27me3 antibodies that displayed acceptable behavior by peptide microarray to test in 
ChIP-Seq. Analysis of wild-type mouse embryonic stem cells showed a strong correlation of 
read distribution between the two antibodies (Figures 4A, 4B, and S4A). To assess the 
specificity of these antibodies for H3K27 methylation, parallel ChIP-Seq experiments were 
performed in ES cells lacking H3K27 methylation due to genetic deletion of the EED core 
subunit of the PRC2 histone methyltransferase complex (Chamberlain et al., 2008) (Figures 
4A, 4B, S4B, and S4C). Meta-analysis of the average signal for each antibody over all 
H3K27 peaks in the genome (n = ~ 8,500) shows that these antibodies are specific and that 
signal is lost in the knockout line (Figure 4B).
While ChIP experiments comparing wild type and histone methyltransferase-null cell lines 
inform on antibody specificity, they can only provide correlative information on epitope 
recognition. We therefore sought to define more directly the specificity of histone PTM 
antibodies for endogenous nucleosomal epitopes by performing IPs of mouse ES cells (E14) 
spiked with a library of semi-synthetic DNA-barcoded mononucleosomes (Internal Standard 
Calibrated ChIP; IceChIP) uniformly modified by H3K4me3, H3K9me3, H3K27me3, 
H3K36me3, and H3K79me2 (Grzybowski et al., 2015). We tested two H3K27me3 
antibodies and two H3K79me2 antibodies using both native and cross-linking IP conditions 
(Figures 4C and 4D). The series of semi-synthetic nucleosomes marked with H3K27me3 
were significantly enriched with both H3K27me3 antibodies under both native IP and cross-
linking conditions. In contrast, H3K79me2 Ab1, but not Ab2, modestly enriched for semi-
synthetic nucleosomes marked with this PTM under native conditions, and neither antibody 
enriched for H3K79me2 nucleosomes under cross-linking conditions. Collectively, these 
data highlight the utility of semi-synthetic nucleosomes for histone PTM antibody 
characterization within ChIP experiments and suggest that the choice to cross-link chromatin 
in a ChIP can have consequences on the resultant IP.
DISCUSSION
Antibody choice is the single most important element of many epigenetic experiments; yet 
there are many widely used commercial preparations available for a given mark, and they do 
not all perform equivalently. In this report, we unveil a database that documents the 
behavior of over 100 histone PTM-specific antibodies on peptide microarrays. This portal 
provides an interactive search tool, allowing investigators to access and compare antibodies 
based on histone type, PTM type, vendor source and other criteria. Importantly, the database 
is built to evolve and grow over time as additional antibodies are characterized. To facilitate 
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community involvement, inclusion of new antibody data can be achieved through 
investigator-supplied or vendor-supplied microarray results using the Upload Data tab in the 
main page portal. A simple user guide walks investigators through the few steps required to 
integrate array results on the webpage. Briefly, after an array is scanned, a three-column 
comma separated value (CSV) file is uploaded that contains a pixel index or spot ID 
number, green signal intensity and red signal intensity. A sample formatted data file is 
available for viewing and downloading on the site. The database and web portal are built 
automatically via Bash script, allowing newly acquired results to be rapidly analyzed and 
added to the site through a curator with minimal effort. As the need for precise 
characterization of an antibody’s target epitope grows, the use of the array platform utilized 
in this report, which is commercially available through multiple vendors including 
EpiCypher and Millipore, will make this possible. Significantly, this database will 
organically grow with minimal support needed, and further, can adapt to changing array 
platforms.
Using the information obtained from the Histone Antibody Specificity Database, we 
highlight several vignettes describing the type of antibody behaviors that are seen with 
antibodies raised against methyllysine, acetyllysine and phosphoserine on histone residues. 
Antibodies examined displayed a variety of results, ranging from very specific target 
recognition to difficulties in recognizing a precise methyl state, acetyl site location and the 
specific target site itself. The antibodies exhibiting these issues could have severe 
consequences in data interpretation, which may depend on the abundance of the on-target 
mark relative to the off-target PTM. Antibody misbehavior may also be application specific 
(e.g., immunoblotting vs. ChIP). Our array findings revealed the capacity of some of these 
antibodies to show the same behavior in various applications, for example western bot 
(Figure 3A) and ChIP (Figure 4). Thus, the results available in the database offer an 
important view of each antibody and what the total possibilities are.
While another available database of antibody specificity is available (Egelhofer et al., 2011), 
this Antibody Validation Database (AVD) specifically offers the demonstration of an 
antibody’s ability to work or not in western or ChIP (e.g., seeing a band in extracts or 
sequencing reads), but does not report on the actual specificities of each antibody for all 
possible target possibilities. We argue that knowing the PTM ‘interactome’ represents the 
fundamental foundation that investigators need to start with when choosing an antibody for 
their studies. Thus, the Histone Antibody Specificity Database is meant to complement the 
AVD, but not replace it. To connect these two databases, we have created hyperlinks to 
query available AVD data for a PTM of interest. These links are accessible by mousing over 
the antibody name on the heat maps (Figure S1B). In addition, users can also query available 
ENCODE data, lot information and link directly to the product page for a given antibody 
from the same window.
It is important to highlight that results from the Histone Antibody Specificity Database may 
not translate to actual results in other applications. As mentioned above, while an antibody 
may show ability to bind with an off-target PTM, it may not be an issue if that off-target 
PTM is not present in a particular cell type, or far less abundant in bulk histones (Lin et al., 
2014). Therefore, careful integration of our microarray data with available mass 
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spectrometry-based proteomics analysis of histone PTMs will allow investigators to predict 
whether off-target antibody behavior may be problematic in their specific application. 
However, there are likely cases where off-target recognition or failure to recognize the 
appropriate methyl or acetyl state can skew results, as shown in Figures 2D, 3C, 3D, 4C, and 
4D. Histone core modifications like H3K79 methylation exemplify this concept. Our 
analysis of H3K79 methyl antibodies shows specificity on peptide arrays (as might be 
expected given the antibodies are raised against peptide antigens), but failure in applications 
where the modification must be recognized in its physiologic state. Since the peptide epitope 
does not represent the nucleosomal context of the mark, these antibodies fail to recognize 
the PTM in non-denaturing conditions (they work in denaturing assays like 
immunoblotting). Thus, as a first pass of selecting the right reagent, array analysis provides 
a high-throughput measure of the scope of on/off target binding. But as the arrays are dense 
surfaces of peptide epitopes, and the antibody is dilute and mono-dispersed, which is an 
excellent surrogate for immunoblotting and for exposed epitopes, the arrays may not 
represent assays like ChIP in that the format is reversed (dense surface of antibody, sparse 
epitope), and the nucleosomes must remain largely intact and folded.
The Histone Antibody Specificity Database represents an invaluable resource and tool for 
the scientific community who rely on histone PTM antibodies as detection reagents in 
chromatin and epigenetics research. Collectively, the data from this web portal will now 
greatly aid in informing investigators about specificity of antibodies they have previously 
used, and the website will enable better decision-making for which reagent to use in future 
experiments among the myriad of commercially available antibodies. It is our hope that 
making this specificity data publicly available will facilitate more informed antibody 
choices, aiding in the interpretation of results obtained with these critical reagents.
EXPERIMENTAL PROCEDURES
Materials
Biotinylated histone peptides (Table S1) were synthesized by Fmoc chemistry, purified by 
reverse phase HPLC and analyzed by MALDI-TOF MS and analytical reverse phase HPLC 
as previously described (Rothbart et al., 2012b). A list of antibodies screened in this study 
can be found in Table S2.
Histone Peptide Microarrays
Array fabrication, antibody detection and data analysis were performed as described 
(Rothbart et al., 2012b) with the following modifications. Each peptide listed in Table S1 
was spotted in triplicate eight times per array. Triplicate spots were averaged and treated as 
a single value for subsequent statistical analysis. Heat maps were generated with Java 
TreeView (Saldanha, 2004).
Cell Culture, Manipulation, and Protein Harvest
HeLa cells (ATCC) were cultured in MEM (Life Technologies) supplemented with 10% 
FBS, maintained in a 37 °C incubator with 5% CO2 and pas saged every 2-3 days. EED-null 
(referred to as KO) embryonic stem cells (Gift from Weipeng Mu and Della Yee) were 
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generated from EED fl/fl (referred to as WT) mouse ES cells transfected with a CAG-Cre-
ERT2 transgene and treated with tamoxifen. Cells were cultured as previously described 
(Chamberlain et al., 2008). For double-thymidine block, HeLa cells were synchronized by 
treatment with 2 mM thymidine (Sigma) for 16 hours, followed by release for 8 hours and 
retreatment with 2 mM thymidine for 16 hours. HeLa cells were lysed in cold buffer 
containing 10 mM PIPES (pH 7.0), 300 mM sucrose, 100 mM NaCl, 3 mM MgCl2, 1× 
EDTA-free protease inhibitor (Roche), 1× phosphatase inhibitor cocktail (Sigma), 0.1% 
Triton X-100 and endonuclease (Pierce) before being resolved by SDS-PAGE. Whole cell 
protein extracts from wild-type (BY4741) and set1Δ Saccharomyces cerevisiae were 
prepared using SUMEB buffer containing 10 mM MOPS (pH 6.8), 1% SDS, 8 M urea, 10 
mM EDTA and 0.01% bromophenol blue. Briefly, 500 ml of buffer and the equivalent 
volume of glass beads were added to approximately 36 O.D. equivalent of cells. Extracts 
were prepared by beating the beads for 6 minutes followed by centrifugation. Cleared 
extracts were serially diluted 2-fold using SUMEB buffer and boiled for 10 minutes at 95°C 
prior to SDS-PAGE and immunoblotting with the indicated antibodies.
ChIP
Wild-type and EED-null ES cells were harvested and fixed for 10 minutes at room 
temperature in 1% formaldehyde in phosphate buffered saline (PBS) and then quenched by 
adding glycine to 0.125 M for 5 minutes at room temperature. 50 μL Protein A and Protein 
G Dynal beads (Life Technologies) were prepared by incubating with 5 μg H3K27me3 
(Abcam ab6002) or 5 μg H3K27me3 (Millipore 07-449) overnight. Cells were sonicated for 
10 cycles of 30 seconds on 1 minutes off using a Bioruptor (Diagenode) to an average size 
or 200-600 bp and incubated overnight with antibody bead complexes. The beads were 
washed 8 times in RIPA buffer (10 mM Tris-HCl ph 8.0, 100 mM NaCl, 1 mM EDTA, 0.5 
mM EGTA, 0.1% Sodium Deoxycholate, 0.5% N-lauroylsarcosine) and eluted in 100 μL of 
1% SDS, 100 mM NaHCO3 for 15 minutes at 65 degrees. Following crosslink reversal 
samples were treated with RNAseA and Proteinase K before purification using a Clean and 
Concentrator ChIP kit (Zymo Research).
Library Preparation
Libraries were prepared using standard methods for Illumina sequencing using NEB Next 
ChIP kits (New England Biolabs) and samples were submitted to the UNC High-Throughput 
Sequencing Facility for sequencing on an Illumina HiSeq2000.
Bioinformatics Analysis
Reads were aligned to the mouse genome (mm10) with bowtie2 using the -sensitive 
parameter (Langmead and Salzberg, 2012) and enriched regions were identified using macs2 
v2.1.0 (Zhang et al., 2008) using the broadpeak setting. Genome browser tracks were 
created using the HTSeq python library (Anders et al., 2015) and are available for use as a 
UCSC Genome Browser track hub (GEO accession #GSE66902) at http://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=cvmbiscshnclfud&acc=GSE66902. 
Comparisons of WT and KO cell lines for each antibody were carried out using R (R Core 
Team (2014)).
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Bar-Coded Designer Nucleosomes Construction
Barcoded semi-synthetic nucleosomes were made as previously described (Grzybowski et 
al., 2015). Posttranslational modifications of histone H3 included: H3K4me3, H3K9me3, 
H3K27me3, H3K36me3, H3K79me2, and unmodified histone H3 (WT).
ICeCHIP
Native ICeChIP was performed with chromatin isolated from mouse ESCs (E14) as 
previously described (Brand et al., 2008). Aforementioned chromatin was doped with semi-
synthetic nucleosomes bearing symmetrical: H3K4me3, H3K9me3, H3K27me3, 
H3K36me3, H3K79me2 as well as non-modified H3; each mark was identifiable by a 
unique DNA sequence. For crosslinked ICeChIP, the same source and amount of digested 
and HAP purified chromatin was subjected to a 15 minute treatment with 0.1% freshly 
cracked formaldehyde at room temperature. Crosslinking was extinguished with 1 volume of 
2× X-link ChIP buffer (66 mM Tris pH 7.5, 300 mM NaCl, 10 mM EDTA, 2% NP-40, 0.5% 
N-lauroylsarcosine). The concentration of chromatin was adjusted to 20 μg/mL with 
appropriate ChIP buffer supplemented with 50 μg/mL BSA (NEB). 16 μL of protein A 
magnetic beads per IP (Dynabeads®) was washed twice with IP buffer 1 (25 mM Tris pH 
7.5, 5 mM MgCl2, 100 mM KCl, 10% (v/v) glycerol, 0.1% (v/v) NP-40 substitute, 50 μg/mL 
BSA (NEB)) and subsequently incubated with 4 uL of antibody per IP (H3K27me3 AB6002 
lot GR137554; H3K27me3 AM39156 lot 29014002; H3K79me2 AM39143 lot 1008001; 
H3K79me2 M04-835 lot DAM1527889). Bead-antibody conjugates were subjected to two 
washes with ChIP buffer 1. Chromatin was incubated with antibody for 10 minutes at 4°C 
on a rotator.
For native ICeChIP, beads were washed twice for 10 minutes at 4°C with ChIP buffer 2 
(25mM Tris pH 7.5, 5 mM MgCl2, 300 mM KCl, 10% (v/v) glycerol, 0.1% (v/v) NP-40 
substitute, 50 μg/mL BSA (NEB)), and once for 10 minutes at 4°C wit h ChIP buffer 3 (10 
mM Tris pH 7.5, 250 mM LiCl, 1mM EDTA, 0.5% Na•Deoxycholate, 0.5% (v/v) NP-40 
substitute), then briefly washed with ChIP buffer 1 and TE buffer, followed by 50 μL ChIP 
elution buffer (50 mM Tris pH 7.5, 1 mM EDTA, 1% w/v SDS) at 65°C for 5 minutes.
For crosslinked ICeChIP, beads were washed three times for 10 minutes at 4°C with RIPA 
buffer (25mM HEPES pH 7.9, 250 mM LiCl, 1mM EDTA, 1% (v/v) NP-40 substitute, 0.5% 
(w/v) N-lauroylsarcosine), then briefly washed with TE buffer, followed by 50 μL ChIP 
elution buffer (50 mM Tris pH 7.5, 1 mM EDTA, 1% w/v SDS) at 65°C for 5 minutes.
Elutions were supplemented with NaCl up to 200 mM, EDTA up to 10 mM and 20 μg of 
proteinase K (Roche) and incubated for 2 hours at 55°C. To purify DNA, 3 volumes of SPRI 
beads (18% PEG8000, 1 M NaCl, 1mg/mL Sera-Mag SpeedBeads carboxylate-modified 
magnetic particles) were added to the elution and pipetted 10 times up and down followed 
by 5 minutes incubation at room temperature. Magnetic beads were collected on the side of 
the tube with a magnet, and two 30 second washes with 200 μL of 80% EtOH on the magnet 
were performed. Tubes were then taken out of magnetic rack and 50 μL of TE buffer was 
added to beads and mixed by pipetting up and down.
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Enrichment of each histone PTM was evaluated by qPCR using TaqMan® chemistry. 
Enrichment was calculated using the ΔΔCt method.
Where df is a dilution factor between IP and input. Subsequently, enrichment for each PTM 
was normalized to the enrichment of the on-target nucleosome (e.g., for H3K27me3 
antibody, on-target would be H3K27me3 semi-synthetic nucleosome). Experiments were 
performed in technical triplicate. Errors were estimated using partial derivation. All ICeChIP 
data has been deposited under GEO accession # GSE60378.
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Refer to Web version on PubMed Central for supplementary material.
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• Peptide microarrays catalogue the specificity of widely-used histone antibodies
• Histone antibodies frequently show difficulties in detecting their intended 
targets
• A Histone Antibody Specificity Database (www.histoneantibodies.com) was 
created
• This resource facilitates more informed antibody choice for epigenetic 
applications
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Figure 1. Histone antibody characterization by peptide microarray and web interface of the 
Histone Antibody Specificity Database
(A) Cartoon depicting the stepwise procedure for peptide microarraying of an antibody from 
peptide immobilization to antibody hybridization and visualization. Positive interactions are 
visualized as red fluorescence. All printed spots show green fluorescence from the 
biotinylated fluorescein (5-FAM) printing control. (B) Posttranslational modifications and 
their combinations on human histones for which antibodies screened to publication date 
(Table S2) are marketed to recognize. Lysine acetylation (ac); Lysine methylation 
(me1/2/3*); Arginine methylation (me1/2a/2s**); Serine and threonine phosphorylation (P). 
*Histone lysine methylation occurs in three forms (mono-, di-, and trimethylation). 
**Arginine methylation also occurs in three forms (monomethylation, symmetric, and 
asymmetric dimethylation). (C) Screenshot of the home page for 
www.histoneantibodies.com, an interactive java-based web resource displaying histone 
antibody specificity data from peptide microarray experiments. Users can query data by 
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entering strings in the search bar and by clicking on their histone and posttranslational 
modification of interest.
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Figure 2. Unfavorable observations of histone PTM antibody behavior
(A) The inability to distinguish the modification state on a particular residue (e.g., mono-, 
di-, or trimethyl lysine). H3K4me3 and H3K4me2 antibodies cross-react with H3K4me2 and 
H3K4me1 peptides, respectively, to varying degrees. Average signal intensities from each 
antibody screened by microarray were normalized to signal from the target peptide 
(H3K4me3, left; H3K4me2, middle; H3K4me1, right). Error is presented as ± S.E.M. from 
at least two arrays. H3K4me3 Ab1 (Millipore 07-473); H3K4me3 Ab2 (Epicypher 
13-0004); H3K4me3 Ab3 (Active Motif 39160); H3K4me3 Ab4 (Abcam ab8580); 
H3K4me3 Ab5 (Abcam ab1012); H3K4me2 Ab1 (Active Motif 39142); H3K4me2 Ab2 
(Epicypher 13-0013); H3K4me2 Ab3 (Abcam ab32356); H3K4me1 Ab1 (Abcam ab8895); 
H3K4me1 Ab2 (Millipore 07-436). (B-C) The influence of neighboring PTMs. (B; Left) 
Binding of H3K9me3 antibodies to their epitopes is inhibited to varying degrees by 
neighboring H3S10 phosphorylation (H3S10p) and vise versa. Average signal intensities 
from each antibody screened by microarray were normalized to signal from the target 
peptide. Error is presented as ± S.E.M. from at least two arrays. H3K9me3 Ab1 (Millipore 
07-442); H3K9me3 Ab2 (Diagenode C15410193); H3K9me3 Ab3 (Active Motif 39161); 
H3K9me3 Ab4 (Abcam ab8898); H3S10p Ab1 (Active Motif 39253); H3S10p Ab2 (Abcam 
ab5176); H3S10p Ab3 (Invitrogen 491041); H3S10p Ab4 (Millipore 04-817); H3K9me3 + 
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S10p Ab1 (Millipore 05-809); H3K9me3 + S10p Ab2 (Abcam ab5819). (C) H4 acetyl 
antibodies prefer poly-acetylated epitopes. Results of at least two arrays are presented as 
heat maps of normalized mean intensities on a scale from 0 (black; undetectable binding) to 
1 (yellow; strong binding). K5ac Ab1 (Active Motif 39169); K5ac Ab2 (Active Motif 
39170); K5ac Ab3 (Millipore 07-327); K8ac Ab1 (Active Motif 39172); K8ac Ab2 
(Epicypher 130021); K12ac Ab1 (Active Motif 39165); K12ac Ab2 (Millipore 04-119); 
K12ac Ab3 (Millipore 07-595); K16ac Ab1 (Active Motif 39168); 4ac Ab1 (Active Motif 
39179); 4ac Ab2 (Millipore 05-1355); Kac Ab1 (Active Motif 39925); Kac Ab2 (Millipore 
06866). (D) Off-target recognition. Scatter plot showing two arrays probed with an 
H3K9me3 antibody (Diagenode C15410193). Analysis of H3K9 methylation states shows 
strong binding to H3K9me3 peptides (blue), and minimal binding to H3K9me1 (yellow) and 
H3K9me2 (grey) peptides. This antibody also binds off-target Kme3 peptides (red). All 
other peptides are shown in black. Coefficient of determination (r2) was calculated by linear 
regression analysis using GraphPad Prism v5.
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Figure 3. Cellular validation of antibody behavior on microarrays
(A-B) H3K27me3 antibodies bind H3K4me3 peptides. (A) Results of at least two arrays are 
presented as heat maps of signal intensities relative to H3(15-34)K27me3 peptides on a scale 
from −1 (blue; undetectable binding) to +1 (yellow; strong binding). Ab1 (Abcam ab6002); 
Ab2 (Millipore 07-449); Ab3 (Active Motif 39156); Ab4 (Active Motif 39155); Ab5 
(Diagenode C1541095). (B) Immunoblots of serially diluted wild-type (BY4741) and set1Δ 
yeast cell extracts. Asterisk demarcates a cross-reactive band unrelated to H3K4me3. 
H3K27me3 Ab2 (Active Motif 39156); H3K4me3 Ab2 (Epicypher 13-0004); H3 
(Epicypher 13-0001). (C-D) H3S10p antibodies bind to the H3 N-terminal tail independent 
of S10 phosphorylation. (C) Results of at least two arrays are presented as heat maps of 
signal intensities relative to H3(1-20)S10p peptides on a scale from −1 (blue; undetectable 
binding) to +1 (yellow; strong binding). Ab1 (Active Motif 39253); Ab2 (Millipore 05-598); 
Ab3 (Abcam ab5176); Ab4 (Invitrogen 491041); Ab5 (Millipore 04-817). (D) Immunoblots 
of HeLa cell extracts at 0, 2.5, 5, 7.5 and 10 hours following release from synchronization 
by double thymidine block. H3S10p Ab1 (Active Motif 39253); H3S10p Ab2 (Millipore 
05-598).
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Figure 4. Validation of antibody behavior by chromatin immunoprecipitation
(A-B) ChIP-Seq analysis using the indicated H3K27me3 antibodies in wild-type (WT) and 
EED-null (KO) mouse embryonic stem cells. (A) Genome browser shot of the Hox cluster. 
(B) Meta-analysis of all H3K27Me3 reads 1kb on either side of transcription start sites (0) in 
WT (black) and KO (red) mESCs. Ab1 (Abcam ab6002); Ab2 (Millipore 07-449). (C-D) 
Immunoprecipitation of DNA barcoded semi-synthetic nucleosome ladders in the presence 
of isolated mouse native chromatin, under (C) native or (D) cross-linked conditions with the 
indicated antibodies. Data is presented as enrichment normalized to on-target nucleosome ± 
S.D. for three technical replicates. H3K27me3 Ab1 (Abcam ab6002); H3K27me3 Ab2 
(Active Motif 39156); H3K79me2 Ab1 (Active Motif 39143); H3K79me2 Ab2 (Millipore 
04-835).
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